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SUMMARY
Nivalenol (NIV) and deoxynivalenol (DON) are structurally related mycotoxins produced by Fusarium fungi. These fungi typically infest cereal crops such as wheat, maize, barley, oats and rye, and NIV and DON are regularly found in cereal grains, food and feed. Recent risk assessments for NIV and DON identified possible data gaps for the two substances, in particular with respect to data on genotoxicity and carcinogenicity. In the evaluation carried out in 2001, WHO/JECFA assessed the genotoxicity data of deoxynivalenol and concluded that it was not mutagenic in bacteria, but chromosomal aberrations were observed in vitro and in vivo, although the overall significance of those results was considered equivocal. Recent studies published after the WHO/JECFA evaluation confirmed the potential of deoxynivalenol to induce chromosomal aberrations or DNA damage in in vitro systems, with some evidences indicating a role of oxidative stress in the in vitro genotoxic potential of the substance.
The overall objective of the project was to assess the genotoxicity of DON and NIV, including the identification of the potential modes of genotoxic action. The results obtained in the battery of in vivo genotoxicity tests with NIV and DON: Comet assay with and without fpg in seven organs (duodenum, colon, blood, liver, spleen, kidney and bone marrow), micronucleus assay in bone marrow and colon, and Pig-a assay in peripheral blood in mice. In addition, to clarify the genotoxic mode of action of mycotoxins, we performed in vitro Comet assay studies in TK6 cells to investigate potential genotoxic oxidative stress induced by mycotoxins. The response in all the genotoxicity assays with NIV after three oral gavage doses at 5, 10 and 20 mg/kg, were uniformly negative.
In the case of DON, we found that DON failed to induce micronuclei formation in bone marrow and colon and failed to induce primary DNA damage in the seven organs/tissues observed by the Comet assay with and with fpg at dose levels of 4, 8 and 16 mg/kg. A non-statistically significant increase in DNA migration was observed in the Comet assay with fpg at 16 mg/kg. A confirmatory study did not show any DNA fragmentation in the Comet assay with OGG1 with DON. The Pig-a assay with DON after three oral gavage doses at 2, 4 and 8 mg/kg, did not showed any mutagenic effect of DON at day 28 and 45 after the last dose.
In vitro studies indicated that both DON and NIV did not induce DNA damage in the Comet assay with or without fpg in TK6 cells after a 3 hour and 24 hour of treatment. GSH depletion in TK6 cells induced by buthionine sulphoximine did not reveal any oxidative DNA damage with NIV and DON.
It was concluded that the two mycotoxins, NIV and DON, could be considered as devoid of genotoxic potential and pose no mutagenic risk.
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BACKGROUND AS PROVIDED BY EFSA
Nivalenol and deoxynivalenol are structurally related mycotoxins produced by Fusarium fungi. These fungi typically infest cereal crops such as wheat, maize, barley, oats and rye, and the presence of nivalenol and deoxynivalenol is regularly found in cereal grains, food and feed. As a consequence of the similar chemical structure, nivalenol and deoxynivalenol have also very similar toxicological profiles, although differences between their toxicological potencies towards various endpoints were also noted.
Recent risk assessments for nivalenol and deoxynivalenol identified possible data gaps for the two substances, in particular with respect to data on genotoxicity and carcinogenicity. In the evaluation carried out in 2001, WHO/JECFA assessed the genotoxicity data of deoxynivalenol and concluded that it was not mutagenic in bacteria, but chromosomal aberrations were observed in vitro and in vivo, although the overall significance of those results was considered equivocal. Recent studies published after the WHO/JECFA evaluation confirmed the potential of deoxynivalenol to induce chromosomal aberrations or DNA damage in in vitro systems, with some evidences indicating a role of oxidative stress in the in vitro genotoxic potential of the substance. Regarding carcinogenicity, a 2-year study evaluated by JECFA showed no increased incidence of neoplastic changes in mice administered DON via the diet. In their conclusions JECFA recommended the generation of further genotoxicity studies and the performance of a long term carcinogenicity study in a second species (rat). The EFSA CONTAM Panel recently adopted a Scientific Opinion on nivalenol (EFSA, 2013) and noted that limited in vitro data on genotoxicity and insufficient data on carcinogenicity are available for nivalenol. The in vitro genotoxicity dataset indicated negative results on mutagenicity but a weak clastogenic potential, similarly to what has been reported for deoxynivalenol in the previous assessments. On the ground of the overall weight of evidence, including the possible role of oxidative stress reported for deoxynivalenol, the CONTAM Panel concluded that nivalenol is unlikely to be genotoxic. However, to support this conclusion, the CONTAM Panel recommended the generation of further genotoxicity data. No firm conclusions could be drawn on the carcinogenicity of nivalenol.
TERMS OF REFERENCE AS PROVIDED BY EFSA
The present call aims to assess the genotoxicity of deoxynivalenol and nivalenol. The identification of the potential modes of action for genotoxicity for the two toxins, including the role of oxidative stress, will be also an objective of the project.
The outcome of this work could serve as a supporting background document for the future Scientific Opinion on deoxynivalenol and for the possible refinement of the Scientific Opinion on nivalenol.
Objectives
The present call aims to generate experimental data for the assessment of in vivo genotoxicity for deoxynivalenol and nivalenol, including the identification of the potential modes of action. Data will be generated by means of a battery of in vivo genotoxicity studies in laboratory animals. The genotoxicity endpoints to be included in the studies will be selected on the ground of the available information for the two toxins. The endpoints for the identification of the modes of action can be included in the main in vivo studies or carried out as separate experiments.
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INTRODUCTION AND OBJECTIVES
The present study is in response to the EFSA call for proposals for in vivo genotoxicity study to evaluate the mutagenic potential of nivalenol and deoxynivalenol and to perform in vitro investigations of the genotoxic mode of action of both toxins.
The aim of this study is to perform an exhaustive evaluation of in vivo genotoxicity potential of NIV and DON in mice after oral administration by using combined genotoxicity tests (Comet assay without and with fpg, micronucleus test in bone marrow and colon, and Pig-a assay in red blood cells) and to perform in vitro Comet assay in TK6 cells with fpg.
MATERIALS AND METHODS
Chemicals
Nivalenol (NIV), deoxynivalenol (DON), agarose, Triton-X100 and ethylenediamine-tetraacetic acid (EDTA), Buthionine sulphoximine (BSO), N-acetylcysteine (NAC) and N-Ethyl-N-nitrosourea (ENU) were purchased from Sigma-Aldrich (Saint-Quentin Falavier, France). Methylmethanesulfonate (MMS) was purchased from Acros Organics (Geel, Belgium). NIV was dissolved in physiological saline with 8 % ethanol. DON and MMS were dissolved in physiological saline. Sodium pentobarbital was provided by Ceva (Libourne, France). Dimethyl sulfoxide (DMSO), phosphate buffer saline (PBS) and Hank's balanced salt solution (HBSS) were obtained from Invitrogen (Cergy Pontoise, France). All other chemicals used in this study were of analytical quality.
2.
In vivo genotoxicity tests with NIV
Animals and treatment
The experiments were approved by the Institute's Ethical Committee on Animal Experimentation. Male Swiss albino mice weighing around 20 g were obtained from Janvier (Le Genest St Isle, France). The animals were acclimatised for at least five days. They were maintained under a 12-hours light/dark cycle in an air condition room at 20-23 C with food and water ad libitum.
Determination of the maximum tolerated dose (MTD) for NIV
A first animal was dosed with a single oral dose of NIV at 40 mg/kg body weight (b.w.). However, due to important toxicity (decrease in bodyweight gain, absence of food consumption and lethargy), the animal was euthanised. A second animal received 3 doses of NIV at 20 mg/kg b.w. per day at 24-hours intervals, and no signs of toxicity were observed. Two other mice were dosed three times with 20 mg/kg b.w. per day of NIV at 24 hour intervals confirming the absence of toxicity. Then the MTD was set at 20 mg/kg b.w. for NIV. Therefore, the doses selected for the genotoxicity experiment were 5, 10 and 20 mg/kg b.w. per day.
Dosing regime with NIV for Comet assay and micronucleus tests
After acclimatisation, animals were divided into five groups (five animals/group). Three groups were treated with NIV. The doses selected for the genotoxicity experiment were MTD (20 mg/kg), MTD/2 (10 mg/kg) and MTD/4 (5 mg/kg). NIV was dissolved in ethanol with further dilution in sterile saline solution (the final concentration of ethanol was 8 % of the final volume). A control group treated with physiological saline with 8 % ethanol and a positive control group (MMS 80 mg/kg) were also included. The gavage schedule followed a daily administration at 0, 24 and 45 hours with a dosing volume of 10 mL/kg. Animal body weights were recorded before each administration. Clinical signs were monitored daily.
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2.1.3.
In vivo alkaline Comet assay
Briefly, individual animals were anesthetised by intraperitoneal injection of 60 mg/kg sodium pentobarbital 3 hours after the last oral administration of the toxin. After collection of blood in a heparinised tube, a perfusion through the heart was set up with 30 mL (3 mL/minute to remove the blood from the main organs. Organs (colon, spleen, kidney, liver, duodenum) were then removed, kept on ice, and rinsed with the HBSS medium with 10 % DMSO. The liver and the kidney were cut into small pieces and minced for 5 seconds using a Medimachine® (Dako, S.A., Trappes, France) to obtain cell suspensions. Spleen cell suspensions were obtained by cutting into small pieces and dissociating the fragments by pipetting. Bone marrow cells were flushed from a femur with 1 mL of fetal calf serum. After rinsing with the HBSS medium with 10 % DMSO using a syringe, intestine (duodenum and colon) were cut longitudinally and scrapped with a glass coverslip. Resulting cell suspensions were filtered through a 50 µm nylon filter, counted and diluted to obtain a final suspension of 50 000-100 000 cells/mL before a centrifugation step at 136 g for 5 minutes. Cell pellets, blood and bone marrow samples (20 µL) were mixed in 500 µL of 0.5 % pre-warmed (37 °C) low melting-point agarose, 65 µL were laid down on slides (4 per sample), which were previously dipped in 1 % agarose, dried, and further pre-coated with 0.8 % agarose. Six slides per sample were dedicated to the alkaline Comet assay and the last three slides were used for detecting oxidative DNA damage with the fpgmodified Comet assay. The slides were then put in a lysis solution (2.5M NaCl, 0.1M EDTA, 10mM Tris-HCl pH 10, extemporarily added with 10 % DMSO and 1 % Triton X-100), for 1 hour at 4°C. DNA was allowed to unwind for 20 minutes in fresh electrophoresis buffer (0.3M NaOH, 1 mM EDTA, pH 13) before electrophoretic migration at room temperature (24 minutes, 0.7 V/cm, 300 mA). The slides were bathed twice for 5 minutes in neutralizing solution (0.4M Tris-HCl, pH 7.5) and dried for conservation with 95 % ethanol for 5 minutes.
In the fpg-modified Comet assay, after lysis incubation, the slides were washed in fpg buffer (40 mM HEPES, 0.1 M KCl, 0.5 mM EDTA, pH 8.0) prior to a 30 minute-incubation with or without fpg (3.6 units/slide) (Sigma-Aldrich) at 37 °C. After two washes with PBS, the following steps (unwinding, electrophoresis and neutralisation) were identical to the alkaline Comet assay procedure.
DNA was stained with propidium iodide (2.5 µg/mL in PBS) just before slide examination with a fluorescence microscope (Leica DMR) equipped with a CCD-200E video camera.
Coded slides were analysed by the Comet Assay IV software (Perceptive Instruments, Haverhill, UK The colon micronucleus test was performed as described previously (Le Hégarat et al., 2006; Poul et al., 2009; Bazin et al., 2010) . Briefly, colon was excised, cut longitudinally, and washed. The tissue was rolled from anus to caecum, fixed in 4 % formalin and embedded in paraffin. Longitudinal sections (5 µm) were deparaffinised and dehydrated prior to staining with Feulgen for nucleus detection, (1-hour hydrolysis in 6 N HCl at room temperature followed by 2-hours soaking in Schiff's reagent), counterstaining with Fast Green, dehydration, mounting in DPX medium, and coding. Intact colon crypts were chosen for scoring at least 1,000 cells per mouse. A micronucleated cell was defined as a cell with a normal nucleus adjacent to one or two micronuclei in the cytoplasm with a diameter never exceeding one-third of the main nucleus. Apoptosis was assessed according to morphological characteristics, such as cell shrinkage, chromatin condensation, and cell fragmentation. Mitotic cells were identified by chromosome detection in cells without cytoplasmic or nuclear shrinkages. Moreover, mitotic figures were horizontally displaced away from the basal epithelial layer toward the crypt lumen. Additional Swiss male mice (Janvier, Le Genest St Isle, France) were used for the Pig-a assay and were divided into five groups of five animals. The same doses and dosing regime as described in section 2.1.2 were used for the Pig-a assay. ENU was used as positive control and was prepared in phosphate buffer saline (PBS).
Blood samples were collected 28 days after the final treatment with NIV and ENU, 45 days after the final treatment with NIV. Blood was sampled by retro-orbital bleeding after isoflurane anaesthesia. Approximately 120 µL of blood were collected into heparinized capillary tubes (Fisher Scientific, . Immediately upon collection, 60 µL of each specimen were transferred to tubes containing 100 µL Anticoagulant Solution where they remained at room temperature for less than 2 hours, after which they were immediately leukodepleted.
2.1.5.3. Cell labelling: high throughput protocol Each 60 µL blood sample was combined with 100 µL Anticoagulant Solution and then platelet/leukocyte-depleted via centrifugation through 3 mL Lympholyte (20 minutes at 800 g). Supernatants were removed and the erythrocyte-enriched pellets were rinsed through the addition and aspiration of 150 µL Buffered Salt Solution. The entire content of each tubes were transferred into 15 mL tubes containing 5 mL of cold Buffered Salt Solution + 2 % FBS. This step was repeated once and the tubes were centrifuged at 235 g for 10 minutes. After centrifugation, as much of supernatant as possible was aspirated. 150 µL of Buffered Salt Solution were added to each tube, cells were resuspended with pipetting, until there is no evidence of aggregation, and 160 µL from each tube were transferred to new 15 mL polypropylene tubes containing 100 µL working anti-CD24-PE solution (50 µL Stock Anti-CD24-PE and 100 µL Stock Anti-CD61-PE per 850 µL Buffered Salt Solution + 2 % FBS). After incubating for 20 minutes at + 4 °C, cell suspensions were transferred to tubes containing 10 mL Buffered Salt Solution + 2 % FBS. Following centrifugation for 5 minutes at 340 g, supernatants were aspirated and 100 µL Working Magnetic MicroBead Suspension were added
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(250 µL Stock Anti-PE MicroBeads per 750 µL Buffered Salt Solution + 2 % FBS). Cells and magnetic particles were mixed and incubated at +4 °C for 20 minutes. Pellets were tapped loose, 10 mL Buffered Salt Solution + 2 % FBS were added to each tube, and the samples were centrifuged for 5 minutes at 340 g. Buffered Salt Solution + 2 % FBS, 1 mL/tube, was added. Samples were resuspended and 10 µL of each were added to tubes containing 990 µL Working Nucleic Acid Dye Solution (per 14.1 mL Buffered Salt Solution + 2 % FBS: 450 µL of Stock Nucleic Acid Dye Solution and 450 µL of Counterbright TM Absolute Counting Beads). These 'Pre-Column' samples were maintained at + 4 °C protected from light until flow cytometric analysis occurred (within approximately 2 hours).
The remainder/majority of each sample was applied to a Miltenyi LS Column suspended in a magnetic field (i.e. using QuadroMACS Separators). Once blood cells fully entered a column, 5 mL of Buffered Salt Solution + 2 % FBS were added and the eluate was collected into a 15 mL polypropylene centrifuge tube. The specimens were centrifuged for 5 minutes at 800 g, supernatants were aspirated, the pellets were tapped loose, and 300 µL Working Nucleic Acid Dye Solution were added to each tube. These "Post-Column" samples were incubated at 37 °C for 30 minutes and were then protected from light until flow cytometric analysis occurred as described below (within approximately 2 hours).
Instrument calibration standard
An Instrument Calibration Standard (ICS) was generated on each day data acquisition occurred. Briefly, ICS consist of approximately 50 % wild-type cells and 50 % mutant-mimicking cells, the latter consisting of RBCs that were processed in parallel with experimental samples but that were not incubated with antibody(s). The resulting samples provided sufficient numbers of RBCs that exhibited a full range of PE and SYTO 13 fluorescence intensities that were useful for optimizing PMT voltages and fluorescence compensation settings. The position of the mutant mimics also provided a rational approach for defining the vertical demarcation line used to distinguish mutant phenotype cells from wild-type cells.
2.1.5.5. Data acquisition: high throughput protocol A FACSCanto II flow cytometer (BD Biosciences) providing 488 nm and 633 nm excitation, running FACSDiva ™ v7.0 software, was used for data acquisition and analysis. Stock filter sets were used, with Nucleic Acid Dye (SYTO 13) fluorescence evaluated in the FITC channel, Anti-CD24-PE fluorescence evaluated in the PE channel, and Counting Bead fluorescence evaluated in the APC channel. Stop modes were based on events. Specifically, for each Pre-Column specimen data acquisition stopped when 1 000 events were reached, while each Post-Column specimen timed out after 10 000 000 events (or 400 seconds) were reached. Using the stock Medium fluidics rate setting, these timeframes provided enough acquired events to reproducibly determine RET, RET CD24− , and RBC CD24− frequencies as described below.
Calculations
The formulas used to calculate RBC CD24− and RET CD24− frequencies based on data from preimmunomagnetic and postimmunomagnetic separation specimens were described previously (Dertinger et al., 2012) . In all cases, RBC CD24− and RET CD24− frequencies are expressed as number per one million total RBC or RET, respectively. All %MNRET, %RET, mutant cell frequencies, averages, and standard error calculations were performed with the Excel ® spreadsheet developed by Litron.
3.
In vivo genotoxicity tests with DON
A previous study was performed by the ANSES and Institut Pasteur of Lille to investigate the in vivo genotoxicity of DON in mice (see Appendix A for details). This previous study followed the same
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methods as stated for NIV, namely the Comet assay in seven organs and the MN in bone marrow and colon. In summary, the MTD of DON was determined as 16 mg/kg b.w (see Section 9 for further details) and after a 3-day oral administration at doses of 4, 8 and 16 mg/kg b.w. per day of DON to mice, the multiple-organ Comet assay (blood, bone marrow, liver, kidney, spleen, duodenum and colon) with and without fpg and the bone marrow and gut micronucleus tests were performed.
Animals and treatments for Comet assay and Pig-a assay
For the present study, male Swiss mice were purchased from Janvier (Le Genest St Isle, France). Animals were divided into five groups (five animals/group). Rodents were allowed to acclimatise for approximately one week before treatment. Water and food were available ad libitum throughout the acclimation and experimental periods. Three groups were treated with DON dissolved in sterile saline solution at MTD (16 mg/kg), MTD/2 (8 mg/kg) and MTD/4 (4 mg/kg) in the first study, but due to deaths of all animals in the high dose group a second study was performed using three groups of five animals treated with DON at 8, 4 and 2 mg/kg b.w at 10 ml/kg b.w, and one group of five animals treated with sterile saline solution and two positive control groups of five animals: MMS at 80 mg/kg b.w for comet assay and ENU at 40 mg/kg b.w. for Pig-a assay. DON was dissolved in sterile saline solution. Animal body weights were recorded before each administration and clinical signs were monitored daily.
Comet assay in blood without and with fpg or hOGG1
Blood samples were collected 3 hours after the final treatment with DON by retro orbital bleeding after isoflurane anaesthesia. Immediately upon collection, blood was mixed with LMP agarose 0.5 % and 75 µL was laid down on slides.
For the experiment in absence and in presence of hOGG1, 6 slides per sample (previously dipped in 1 % agarose, dried, and further pre-coated with 0.8 % agarose) were prepared. Four slides per sample were dedicated to the alkaline Comet assay following and the three other were used for detecting oxidative DNA damage with the hOGG1-modified Comet assay. The Comet assay was performed as described above (see section 2.1.3).
For the experiment in absence and in presence of fpg, following a 40-minute electrophoresis, 6 slides per sample were prepared. Four slides per sample were dedicated to the alkaline Comet assay following a 20 and a 40-minutes electrophoresis (2 slides per condition) and the last two slides were used for detecting oxidative DNA damage with the fpg enzyme-modified Comet assay. The Comet assay was performed as described above, but 100 cells per slide were chosen for genotoxicity assessment.
3.3.
Pig-a assay
The same set of animals used in the Comet assay in blood (Section 3.2) was used for the Pig-a assay. See Section 2.1.5 for technical details.
Identification of the potential modes of action for genotoxicity of DON and NIV
4.1.
In vitro Comet assay with NIV and DON in TK6 cells
Cell culture and treatment
The human TK6 lymphoblastoid cell line was maintained as suspension cultures in RPMI 1640 medium with Glutamax™ and supplemented with 10 % FCS, 100 IU/mL penicillin and 100 µg/mL streptomycin. The average doubling time of the TK6 cells was 10-12 hours. TK6 cells
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(2 × 10 5 cells/mL) were treated with DON or NIV in 5 % FCS culture medium for 3 and 24 hours in 12-well plates. NIV and DON were used at concentrations between 1.56 and 25 µg/ml and 0.25 and 1.5 µg/ml for 3 and 24 hours of treatment, respectively. For GSH depletion with BSO, TK6 cells were exposed to BSO at 200 µM for 24 hours before mycotoxin exposure and were exposed to NAC for 2 hours before toxin exposure and also during toxin exposure.
4.1.2.
In vitro Comet assay with fpg
After treatment, 50 µL of cell suspension were mixed with 50 µL Trypan Blue for cell counts and determination of the relative population doubling (RPD). Remaining cells were centrifuged for 5 minutes at 136 g and cell pellets were suspended in pre-warmed low melting point agarose (0.5 % in PBS) and deposited on conventional microscope slides (initially dipped in 1 % agarose and dried) precoated with normal agarose (0.8 % in PBS). The slides were then put in a lysis solution (2.5 M NaCl, 0.1 M EDTA, 10 mM Tris-HCl pH 10, extemporaneously added with 10 % DMSO and 1 % Triton X-100), for 1 hour at + 4 °C. The slides were washed in fpg buffer (40 mM HEPES, 0.1 M KCl, 0.5 mM EDTA, pH 8.0) prior to a 30 minutes-incubation with or without fpg (3.6 units/slide) (SigmaAldrich) at 37 °C. After two washes with PBS, DNA was allowed to unwind for 40 minutes in fresh electrophoresis buffer (0.3 M NaOH, 1 mM EDTA, pH 13) before electrophoretic migration at room temperature (24 minutes, 0.7 V cm -1 , 300 mA). The slides were bathed twice for 5 minutes in neutralizing solution (0.4 M Tris-HCl, pH 7.5) and dried for conservation with ethanol 95 % for 5 minutes. DNA was stained with propidium iodide (2.5 µg/mL in PBS) just before slide examination with a fluorescence microscope (Leica DMR) equipped with a CCD-200E video camera. At least 100 cells per dose and treatment time were analysed using the Comet Assay IV software (Perceptive Instruments, Haverhill, UK). The extent of DNA damage in individual cells was evaluated by the percentage of Tail intensity. Three independent experiments were conducted.
Statistical analysis
Statistical analyses were carried out using GraphPad PRISM 5 (GraphPad Software Inc., San Diego, CA, USA). A one-way analysis of variance (ANOVA) for multiple comparisons on each organ followed by a Dunnett's multiple comparison test was performed for the Comet assays. The comparison of micronucleated cells proportions in bone marrow and gut was performed by a Chisquare test. In all tests, data were considered significantly different when p < 0.05. For Pig-a assay mutant cell frequencies were square root transformed. Each time point was studied separately, where the effect of treatment on these transformed MN-RET, RBCCD24−, and RETCD24−data was compared to vehicle control using Dunnett's multiple comparison t-tests in the context of a one-way analysis of variance model (Stat view®, version 5). Significance was evaluated at the 5 % level using a one-tailed test for increases relative to vehicle control. These same analyses were performed with % RET data, however in this case data were not log transformed, and the tests were two-tailed.
Guidelines and testing principles
The studies were conducted in accordance, and compliance, with international guidelines and recommendations and according to good laboratory practice (GLP). Bone marrow micronucleus tests were performed following the OECD guideline N°474, and the in vivo Comet assay was performed following EFSA recommendations and previous published studies (Gaudin et al., 2008; Bazin et al., 2012; EFSA, 2012) .
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RESULTS
Determination of the maximum tolerated dose (MTD) for NIV
The dose range was established considering the lethal dose 50 % (LD 50 ) for NIV fixed at 40 mg/kg in mice and previous studies showed that no death, no morbidity, and no macroscopic effect on various organs were observed after a single oral dose of 20 mg/kg b.w. in male ICR mice (Tsuda et al., 1998; Ryu et al., 1988) .
A first animal was dosed with a single oral dose of NIV at 40 mg/kg b.w. and due to important toxicity observed (decrease of bodyweight gain, absence of food consumption and lethargy), the animal was euthanised. A second animal received a triple dose of NIV at 20 mg/kg b.w. at a 24 hour interval, and no signs of toxicity were observed. Two other mice were dosed with 3 doses of 20 mg/kg b.w. per day of NIV at 24 hour intervals and no sign of toxicity was observed. The MTD was identified as 20 mg/kg b.w. for NIV, therefore the doses selected for the genotoxicity experiment were 5, 10 and 20 mg/kg b.w. per day.
8.
Toxicity effect on mice exposed to NIV
No mortality, no clinical signs, no disturbance in behaviour, no significant reduction in body weight ( Figure 1 ) and no macroscopic effect on organs were noticed in any groups during and at the end of the 3-day treatment period with NIV. 
Alkaline Comet assay
As shown in Figure 2 , for all organs and tissues selected (blood, bone marrow, liver, kidney, spleen, duodenum and colon), low levels of DNA migration (median of % tail DNA always lower than 5 %) 14 with low variability were observed for the vehicle control group. DNA damage and % of hedgehog cells (cloud cells) were significantly increased in all examined tissues and organs from the positive control group treated with 80 mg/kg MMS (Figure 2 and 3) .
NIV did not significantly increase in DNA migration irrespective of the organ or tissue (Figure 2) and irrespective of the DNA migration parameter used (Table 1 ). The percentage of hedgehog cells was not increased by NIV treatment; however, variability in the duodenum and in the colon was larger than that observed in the other organs (Figure 3) or even in the control group. This phenomenon would be due to the rapid turnover of the intestinal epithelium and the heterogeneity of intestinal cells. 
Fpg-modified Comet assay
In the fpg-modified Comet assay, only hedgehog cells which failed to be detected by the software were observed in all tissues from MMS treated mice (Table 1 ). This result indicated that high levels of oxidised-and/or alkylated-bases and/or FaPy lesions were induced by MMS.
Similarly to the standard alkaline Comet assay, NIV failed to increase DNA migration in all organs investigated in the fpg-modified Comet assay ( Figure 4 and Table 1 ).
On the other hand, in the kidney and the spleen, statistically significant decreases in DNA migration were observed in the group treated with NIV at 10 mg/kg body whatever the parameter used (Table 1 and Figure 4) . Moreover, in the kidney, the percentage of hedgehog cells was statistically significantly decreased in animals treated with NIV at 20 mg/kg body ( Figure 5 ). The present document has been produced and adopted by the bodies identified above as author(s). In accordance with Article 36 of Regulation (EC) No 178/2002, this task has been carried out exclusively by the author(s) in the context of a grant agreement between the European Food Safety Authority and the author(s). The present document is published complying with the transparency principle to which the Authority is subject. It cannot be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors. 
Bone marrow micronucleus test
The positive control MMS clearly increased the frequency of MN PCE.
No induction of MN formation was observed in mice treated with NIV and NIV treatment which did not significantly affect the ratio PCE/NCE (Table 2) . 
Colon micronucleus test
The in vivo colon MN assay in mice provides information on the frequencies of micronucleated, mitotic and apoptotic cells. NIV did not induce micronucleus formation in colon cells after a 3-day administration between 5 and 20 mg/kg b.w. per day (Figure 6 ). A dose-dependent decrease in mitotic 
8.6.
Pig-a assay on peripheral blood cells of mice exposed to NIV
The frequency of mutant phenotype reticulocytes and erythrocytes (RET CD24-and RBC CD24-, respectively) was measured to examine the genotoxic effect of NIV. In general, NIV exposure did not result in increased mean frequencies of mutant phenotype cells at both post-exposure time points, 28 and 45 days, after the final dose. Whereas the positive control ENU clearly increased mutant phenotype cells at day 28 (Table 3 ).
The percentage of RETs (% RET) is the ratio of newly formed RNA-positive erythrocyte relative to all erythrocytes, and is used as a measure of bone marrow cytotoxicity. NIV treated mice did not exhibit any changes in % RET at 28 and 45 days post final dose, whereas ENU increased % RET at day 28. 
In vivo genotoxicity tests with DON
The findings from the in vivo genotoxicity studies performed previously by ANSES and IPL with DON in mice are included in Appendix A. In summary, the aim of that study was to determine the The present document has been produced and adopted by the bodies identified above as author(s In the previous study, the results indicated that DON did not increase DNA migration in the Comet assay without fpg in seven tested tissues (duodenum. colon, blood, liver, spleen, kidney and bone marrow). Fpg-modified Comet assay in blood at the highest dose of DON (16 mg/kg) show inconsistent results, as only three out of five animals showed an increase of DNA migration compared to controls. This effect is probably due to oxidative stress. In the bone marrow micronucleus test, DON decreased the ratio of PCE/NCE without any increase of erythrocyte-micronucleated frequencies. In the colon MN test, although no increase of MN frequencies with DON was detected, a higher level of mitotic figures at the lowest dose of 4 mg/kg b.w. per day, as well as apoptosis induction and cell cycle inhibition at the highest dose were reported.
In this present study, we performed a confirmatory study using the modified Comet assay (with and without fpg and hOGG1) on blood cells combined with the Pig-a assay in the same set of animals.
In the first study, the same doses of DON that were used in the previous study were administered (4, 8 and 16 mg/kg b.w. per day), and OGG1-modified Comet assay was performed 3h after the last dose. However, all the mice of the higher dose group of 16 mg/kg b.w. per day died 2 days after the last gavage, therefore the Pig-a assay could not be performed. The death of all mice in the high dose group could be explained by the fact that in the previous study all the mice were sacrificed 3 hours after the last dose and it is possible that this dose was higher than the MTD. Moreover, the high toxicity of DON indicated that the lethal dose and the MTD are very close. Then, a second study was carried out at lower doses of DON (2, 4 and 8 mg/kg b.w. per day) and fpg-modified Comet assay was performed in blood cells 3 hours after the third gavage and the Pig-a mutation assay was performed in the same set of animals at 28 and 45 days after the final dose.
hOGG1-modified Comet assay on blood cells of mice exposed to DON at 4, 8 and 16 mg/kg b.w. per day
In this study, mice were exposed to DON at doses of 4, 8 and 16 mg/kg b.w. per day for 3 days by oral gavage and blood cells were collected in vein tail to perform the Comet assay. Results showed that DON failed to increase DNA fragmentation in the presence and in the absence of hOGG1 (Figure 7 ), even at the lethal dose of 16 mg/kg b.w. per day.
A statistically significant decrease in DNA fragmentation was noted at both lowest doses of DON and could suggest the formation of interstrand cross-links which block the migration of DNA, however a short time of electrophoresis duration of 20 minutes is not enough to detect crosslinks. Crosslinks can be detected by increasing the duration of electrophoresis to such an extend that control cells exhibit significant DNA migration, demonstrating the effect of crosslinking by a retardation in the extent of DNA migration in comparison with the control. Therefore, in order to ensure that DON do not induced crosslinks, it was decided to increase the duration of electrophoresis in the next study (Nesslany et al., 2007 ) (see Section 9.2).
w. per day
A new in vivo Comet assay study was performed by using lower doses of DON: 2, 4 and 8 mg/kg b.w. per day. Three hours after the third dose, blood cells were collected and fpg-modified Comet assay was performed (Figure 8 ). With fpg, a significant increase in DNA migration at the lower dose of DON, 2 mg/kg b.w. per day, was observed but could be considered without biological significance due to the absence of dose-dependent increase in DNA migration.
No decrease of DNA migration was observed in blood cells in absence of fpg, as observed in the previous study (see Section 9.1). But to confirm the absence of DNA cross-linking with DON, we increased the duration of electrophoresis to 40 minutes and we did not observe a retardation of DNA migration in blood cells exposed to DON compared to negative control ( Figure 9 ).
9.3.
Pig-a assay on peripheral blood cells of mice exposed to DON
The frequency of mutant phenotype reticulocytes and erythrocytes (RET CD24-and RBC CD24-, respectively) was measured to examine the genotoxic effect of DON. In general, DON exposure did not result in increased mean frequencies of mutant phenotype cells at the two post-exposure time points. Only a statistically significant increase in mutant phenotype erythrocytes RBC CD24-was observed 28 days following the final dose of 2 mg/kg b.w. per day, whereas no increase of mutant The present document has been produced and adopted by the bodies identified above as author(s). In accordance with Article 36 of Regulation (EC) No 178/2002, this task has been carried out exclusively by the author(s) in the context of a grant agreement between the European Food Safety Authority and the author(s). The present document is published complying with the transparency principle to which the Authority is subject. It cannot be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.
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frequency was observed 45 days following the final dose for both phenotypes. The positive control ENU clearly increased the frequency of mutant phenotype cells 28 days following the final dose.
The percentage of RETs (%RET) is the ratio of newly formed RNA-positive erythrocyte relative to all erythrocytes, and is used as a measure of bone marrow cytotoxicity. DON treated mice did not exhibit any changes in %RET 28 and 45 days following the final dose. 
Identification of potential mode of genotoxic action of NIV and DON in vitro in TK6 cells
Based on all available data on the in vitro and in vivo genotoxicity of mycotoxins, the enzymemodified Comet assay in vitro was used to determine the mode of genotoxicity action (MoGA) of DON and NIV. In fact, the standard Comet assay was modified to detect oxidised bases by introducing an incubation of the nuclei (just after lysis) with bacterial DNA repair enzymes, such as fpg (Collins, 2013) . The enzyme combines a specific glycosylase activity, removing the damaged base and creating an apyrimidic (AP) site, and an AP lyase which converts the AP site to break. Formamidopyrimidine DNA glycosylase (fpg) acts on 8-ox-7,8-dihydroguanine (8-oxo-guanine). Fpg also recognises some alkylation damage, namely N7-alkylguanines (Speit et al., 2004) .
Fpg-modified Comet assay in vitro in human TK6 cells with NIV and DON
TK6 cells were exposed for 3 h or 24 h in the presence of NIV and DON, and the relative population doubling (RPD) was determined after the treatment, only for the 24 h time of exposure, to assess the cytotoxic effect induced by the toxins. It was found that both toxins induced important cytotoxicity effects in TK6 cells with a decrease in cell division compared to control at concentrations between 0.25 and 1.5 µg/mL (Figure 10 ). Moreover, generally DON induced more pronounced effect than NIV in particular at low concentrations. Both toxins did not induce any significant increase in DNA migration in the Comet assay either without or with fpg in TK6 cells after a short and a long time of exposure ( Figure 10) . After a short time of exposure of 3 h, NIV and DON at concentrations between 1.56 and 25 µM failed to increase DNA migration in TK6 cells, whereas the positive MMS well increased DNA migration. More, only hedgehog cells, which failed to be detected by the software, were observed in the fpg-modified Comet assay in TK6 with MMS.
Fpg-modified Comet assay in vitro in human GSH-depleted TK6 cells by BSO with NIV and DON
In order to investigate the effect of glutathione depletion on the induction of oxidised DNA bases by mycotoxins, TK6 cells were pre-treated with BSO one day before mycotoxins exposure and the fpgmodified Comet assay was performed after 24 hours of exposure. The BSO pre-treatment did not significantly increase DNA migration in TK6 cells exposed to NIV or DON in the two Comet assay protocols with or without fpg (Figure 11 ).
The present document has been produced and adopted by the bodies identified above as author(s). In accordance with Article 36 of Regulation ( 
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DISCUSSION
No exhaustive in vivo genotoxicity studies of mycotoxins NIV and DON have been reported to date whereas consumers are largely exposed to these compounds in food. That is why in order to characterise the genotoxic hazard of these two toxins, generation of further genotoxicity data is recommended.
Firstly, in this present study it was found that NIV was devoid of genotoxic effects in mice after three oral doses at 5, 10 and 20 mg/kg b.w. per day using the multiple organ Comet assay (blood, bone marrow, liver, kidney, spleen, duodenum and colon), the micronucleus test in bone marrow and colon and the Pig-a assay. Moreover, the fpg-modified Comet assay did not show any oxidative DNA damage in any of the organs examined. It is the first study that investigated the genotoxic and the mutagenic effects of NIV by using international guidelines and recommendations. These results are in accordance with previous studies that showed negative results in chromosome aberration test in bone marrow cells of Chinese Hamster after 6 oral administrations of 0.1 LD 50 at three week intervals (Bárta et al., 2001) and no induction of mutations in the forestomach, kidneys, urinary bladder, large intestine, lungs, liver, bone marrow and spleen, (FSCJ, 2010) . However, some studies indicated positive results in the comet assay with NIV: positive results were found in the liver and stomach of mice after 4 oral gavage doses of 6 mg/kg, administered at weekly intervals and in stomach, jejunum, colon, kidney and bone marrow after a single oral dose of 20 mg/kg in mice and also in colon after intraperitoneal injection of 3.7 mg/kg of DON (Tsuda et al., 1998; FSCJ, 2010) . However, these studies did not fulfil the minimal criteria defined in the comet assay recommendations which have been recently published (EFSA, 2012) .
Secondly, we found that DON is also devoid of genotoxic effect in mice after three oral doses between 2 and 16 mg/kg b.w. per day using the multiple organ Comet assay (blood, bone marrow, liver, kidney, spleen, duodenum and colon), the micronucleus test in bone marrow and colon and the Pig-a assay. In addition, the fpg-modified Comet assay did not show any oxidative DNA damage in any of the organs examined. It is the first study that investigated the genotoxic and the mutagenic effects of DON by using international guidelines and recommendations. We observed that DON was more toxic for mice than NIV after oral gavage. In fact, the MTD of DON was between 10 to 15 mg/kg b.w., compared to a MTD of 20 mg/kg b.w. for NIV. The difference in the toxicity of two toxins seems related to their pharmacokinetics parameters and a more efficient intestinal absorption of DON than NIV (Avantaggiato et al., 2004) . Although positive results were obtained in the chromosomal aberrations test in bone marrow of mice receiving 3 mg/kg b.w. of DON by oral gavage, 2 times per week for 8 weeks, this study was qualified as dubious by JECFA because only chromosome gaps were scored (Bilgrami et al., 1993) . Moreover, no increase of chromosomal aberrations were observed in bone marrow when mice were fed with diet containing DON (0.06 mg/kg per day) (Bilgrami et al., 1993) . Others studies showed DNA damage in leukocytes visualised by the comet assay in male chickens fed for 17 days with 10 mg DON /kg feed (Frankič et al., 2006; Awad et al., 2014) , however these studies did not fulfil international recommendations with regards to the conduct of the in vivo Comet assay.
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CONCLUSIONS
In order to address the question about the in vivo genotoxicity potential of NIV and DON, an exhaustive battery of in vivo genotoxicity assays covering all genetic events leading to genotoxicity were conducted in mice: alkaline comet assay with and without fpg in seven organ (blood, bone marrow, liver, kidney, spleen, duodenum and colon), micronucleus tests in bone marrow and colon and Pig-a mutation assay in peripheral blood cells.
The response in the all in vivo genotoxicity assays with NIV after three oral gavage doses at 5, 10 and 20 mg/kg, were uniformly negative. Then NIV failed to induce:
-primary DNA damage in seven organs detected by the comet assay with or without fpg, -numerical and/or structural chromosomal aberrations in bone marrow and colon cells, -gene mutations in reticulocytes and erythrocytes in the Pig-a assay.
All the data suggest that NIV could be considered as not genotoxic in vivo. Moreover, in vitro studies performed in TK6 cells failed to show any primary DNA damage induced by NIV in the fpg-modified Comet assay, suggesting the absence of oxidative DNA bases potential of NIV.
In the case of DON, in both the previous and present studies negative results were observed in all genotoxicity tests at the dose levels of 4, 8 and 16 mg/kg (Comet assay in seven organs, micronucleus test in bone marrow and colon). Only a non-statistically significant increase in DNA fragmentation was observed in the fpg-modified comet assay at the highest dose of 16 mg/kg in blood cells. However, a supplementary hOGG1-modified comet assay in blood cells collected 3 hours after the third treatment with DON at the same dose levels showed no increase in DNA migration.
In addition, all mice from the highest treated group, i.e. 16 mg/kg, died within 2 days after the last dose, suggesting that positive results found at 16 mg/kg in the comet assay with fpg in blood cells in the previous study could not be considered reliable due to high toxicity. The deaths of all mice in the high dose group could be explain by the fact that in the previous study all the mice were sacrificed 3 h after the last gavage and it is possible that this dose was higher than the MTD. In addition, the high toxicity of DON indicated that the lethal dose and the MTD are very close. The hOGG1-modified Comet assay performed following dosing at 4, 8 and 16 mg/kg b.w. per day, for 3 consecutive days did not show any increase in DNA migration in blood cells of mice 3 hours after the last oral administration of DON. Furthermore, in the second fpg-modified Comet assay in blood cells at a lower range of doses of DON, i.e. 2, 4 and 8 mg/kg b.w. per day, administered over 3 consecutive days a statistically significant increase in DNA migration was found at the lowest tested dose of 2 mg/kg b.w. per day, whereas no effect was observed at either 4 or 8 mg/kg b.w.. In the Pig-a mutation assay performed on the same set of animals, a statistically significant increase in Pig-a RBC mutants only (CD24-) was observed at the lowest dose of 2 mg/kg b.w. of DON exclusively at day 28 post final dose and was not confirmed at day 45 post final dose, while no effects were observed in RET population and at higher doses of 4 and 8 mg/kg b.w. per day of DON. In vitro studies performed in TK6 cells revealed no induction of oxidised DNA bases by DON. Taken together these results indicate that DON failed to induce any genotoxic and mutagenic effect in vivo and in vitro studies.
In conclusion, from the overall results obtained in the battery of in vivo genotoxicity tests with NIV and DON, NIV and DON are considered to be devoid of any genotoxic or mutagenic potential.
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The present document has been produced and adopted by the bodies identified above as author(s From the range-finding experiment, MTD of DON was determined as 16 mg/kg, owing to the occurrence of some signs of toxicity at 20 mg/kg. Therefore, the doses selected for the genotoxicity experiment were 4, 8 and 16 mg/kg/day. No mortality, no clinical signs, no disturbance in behaviour, no significant reduction in body weight and no macroscopic effect on organs were noticed in any groups during and at the end of the 3-day treatment. However, a reduction in body weight gain at 48h was observed for 8 and 16 mg/kg/day of DON, when compared with vehicle controls. Moreover, after the last administration of 16 mg/kg/day DON, two mice exhibited a decreased locomotor activity.
After acclimatisation, animals were divided into 5 groups (5 animals/group). Three groups were treated with DON. DON was dissolved in sterile saline solution. The doses selected for the genotoxicity experiment were MTD (16 mg/kg), MTD/2 (8 mg/kg) and MTD/4 (4 mg/kg). A control group treated with physiological saline and a positive control group (MMS 80 mg/kg) were also included. The gavage schedule followed a daily administration at 0, 24 and 45 h with a volume of 10 mL/kg. Animals were sacrificed three hours after the final dose administration. Animal body weights were recorded before each administration. Clinical signs were monitored daily.
Comet assay with and without fpg and MN test in bone marrow and colon were performed as previously described (see section 2.1.3 and 2.1.4, respectively).
Results
Comet assay in various tissues from male mice, 3 hours after a triple dose of DON without and with Fpg
It was noticed that the means of %DNA in tail for the vehicle control groups in seven tissues/organs were low and were inferior of 5 % for all tissues. In contrast, the positive control clearly induced DNA damage in all organs. DON failed to increase DNA damage in all organs observed.
